Neurodegenerative dementia with fluctuating cognition, recurrent visual hallucinations, parkinsonism, and REM sleep behavior disorder.
Also known as: DLB, Lewy body dementia, LBD, diffuse Lewy body disease
Overview
A neurodegenerative dementia in the alpha-synucleinopathy family, defined by progressive cognitive decline plus core clinical features: fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, and one or more cardinal features of parkinsonism. By the '1-year rule,' cognitive symptoms begin before or within 1 year of parkinsonism (distinguishing DLB from PD dementia).
Epidemiology
Accounts for 5-15% of dementia in autopsy series; second or third most common neurodegenerative dementia after Alzheimer disease. Mean onset 60-80 years. Male predominance.
Try two board-style Dementia with Lewy Bodies questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1NeurologyMedium
A 68-year-old female has a 3-month history of progressive cognitive decline, visual hallucinations, and Parkinson-like features (rigidity and bradykinesia) that preceded the dementia by 6 months. She is extremely sensitive to haloperidol, developing severe rigidity after a single dose. Which of the following is the most likely diagnosis?
AAlzheimer disease
BDementia with Lewy bodies
CVascular dementia
DParkinson disease dementia
Reveal answer & full explanation
Correct answer: B — Dementia with Lewy bodies
AAlzheimer disease
BDementia with Lewy bodies✓
CVascular dementia
DParkinson disease dementia
Why Dementia with Lewy bodies is correct
Core features of dementia with Lewy bodies (DLB): (1) fluctuating cognition, (2) recurrent complex and detailed visual hallucinations, (3) parkinsonism, (4) REM sleep behavior disorder
The timing distinguishes DLB from Parkinson disease dementia (PDD): DLB = dementia precedes or is concurrent with motor features (dementia within 1 year of parkinsonism); in this patient parkinsonism preceded dementia by only 6 months
Neuroleptic sensitivity (severe and potentially fatal worsening of parkinsonism and autonomic instability) is a hallmark; typical and most atypical antipsychotics are ABSOLUTELY CONTRAINDICATED
Why the others are wrong
A) Alzheimer disease — gradual memory-predominant decline; no parkinsonism, no visual hallucinations as early features; no neuroleptic sensitivity
C) Vascular dementia — stepwise decline, focal neurologic deficits, cerebrovascular disease on imaging; not associated with parkinsonism or neuroleptic sensitivity
D) Parkinson disease dementia — motor features precede dementia by more than 1 year; clinical overlap with DLB is real, but the 6-month interval here favors DLB by convention
Additional high-yield points
Treatment: rivastigmine (cholinesterase inhibitor — FDA-approved for DLB) for cognitive symptoms
Levodopa for motor features
Clonazepam for REM sleep behavior disorder (RBD); melatonin is an alternative
Question 2NeurologyMedium
A 74-year-old man is evaluated for an 18-month history of cognitive decline marked by pronounced day-to-day swings in alertness and recurrent, well-formed visual hallucinations of small animals in his home. His wife reports that for several years he has shouted and thrashed during sleep as if acting out dreams. On exam he has symmetric bradykinesia and rigidity with minimal tremor. MRI shows relative sparing of the medial temporal lobes, and DaTscan reveals reduced striatal dopamine transporter uptake. Which of the following best explains his fluctuating cognition and visual hallucinations?
ABeta-amyloid plaque deposition in the hippocampal cortex
BCholinergic neuron loss in the nucleus basalis of Meynert
CIschemic small-vessel disease of subcortical white matter
DDopaminergic neuron loss in the substantia nigra pars compacta
Reveal answer & full explanation
Correct answer: B — Cholinergic neuron loss in the nucleus basalis of Meynert
ABeta-amyloid plaque deposition in the hippocampal cortex
BCholinergic neuron loss in the nucleus basalis of Meynert✓
CIschemic small-vessel disease of subcortical white matter
DDopaminergic neuron loss in the substantia nigra pars compacta
Why Cholinergic neuron loss in the nucleus basalis of Meynert is correct
Dementia with Lewy bodies is an alpha-synucleinopathy: misfolded alpha-synuclein aggregates into Lewy bodies across cortical, limbic, brainstem, and autonomic neurons.
Severe loss of cholinergic neurons in the nucleus basalis of Meynert is the deficit most tied to the cognitive fluctuations and recurrent well-formed visual hallucinations of DLB.
This is why cholinesterase inhibitors (rivastigmine, donepezil, galantamine) are especially effective in DLB, often more so than in Alzheimer disease, reducing hallucinations and improving cognition.
Why the others are wrong
Dopaminergic neuron loss in the substantia nigra pars compacta is real in DLB, but it produces the parkinsonism (bradykinesia, rigidity, reduced DaTscan uptake), not the hallucinations or cognitive fluctuations the lead-in asks about.
Beta-amyloid plaque deposition in the hippocampal cortex is the mechanism of Alzheimer disease, which is memory-dominant with prominent hippocampal atrophy; here memory is relatively preserved and MRI spares the medial temporal lobes.
Ischemic small-vessel disease of subcortical white matter is the mechanism of vascular dementia, which causes stepwise decline with focal deficits and white matter or infarct changes on MRI, not the fluctuation-plus-hallucination picture with a sparing-pattern MRI seen here.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Dementia with Lewy Bodies outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
REM sleep behavior disorder (~80% of patients with idiopathic RBD develop a synucleinopathy within 10-15 years)
Family history of PD or dementia
GBA, SNCA, and APOE-ε4 alleles (modifiers)
Pathophysiology
Aggregation of misfolded alpha-synuclein into Lewy bodies and Lewy neurites within cortical, limbic, brainstem, and autonomic neurons. Cholinergic deficits (severe loss of nucleus basalis of Meynert neurons) contribute to cognitive fluctuations and visual hallucinations; dopaminergic loss in substantia nigra produces parkinsonism.
Clinical presentation
Symptoms
Cognitive fluctuations: pronounced day-to-day or hour-to-hour variation in attention, alertness, and coherence
Recurrent visual hallucinations — typically well-formed people or animals, often non-threatening
REM sleep behavior disorder — dream enactment, often years before cognitive decline
Parkinsonism: bradykinesia, rigidity, gait disturbance; tremor less prominent than in PD
Severe neuroleptic sensitivity — sometimes the presenting clue when an antipsychotic provokes rigidity, confusion, or NMS
Parkinsonian motor exam (symmetric bradykinesia and rigidity > rest tremor)
Postural instability and gait impairment
Cognitive testing: deficits in attention, executive function, and visuospatial processing (clock draw, pentagons)
Memory often relatively preserved early — distinguishes from AD
Classic findings
Elderly patient with fluctuating cognition + well-formed visual hallucinations + parkinsonism + history of acting out dreams.
Differential diagnosis
Alzheimer disease — Memory dominant, gradual progression, less fluctuation, hallucinations later; CSF Aβ42/tau ratio and amyloid PET differentiate
Parkinson disease dementia — Parkinsonism precedes cognitive decline by >1 year (1-year rule); otherwise pathologically and clinically overlap with DLB
Cholinesterase inhibitors — rivastigmine (oral or transdermal), donepezil, galantamine — among the most responsive dementias to these agents; reduce hallucinations and improve cognition
Memantine — adjunct in moderate-severe disease
Carbidopa-levodopa for parkinsonism — start low, titrate slowly; full PD doses risk worsening hallucinations and confusion
Clonazepam (low dose) or melatonin (3-12 mg) at bedtime for REM sleep behavior disorder; melatonin generally preferred in DLB due to less cognitive impact
Psychosis management
First, reduce or stop offending medications (anticholinergics, dopamine agonists, amantadine)
Pimavanserin (selective 5-HT2A inverse agonist) — preferred when pharmacotherapy needed; FDA-approved for PD psychosis with growing DLB use
Low-dose quetiapine or clozapine if pimavanserin unavailable
STRICTLY AVOID typical antipsychotics (haloperidol, fluphenazine) — risk of severe neuroleptic sensitivity reaction (rigidity, hyperthermia, autonomic instability, death)
Excessive daytime sleepiness: address sleep architecture, careful use of modafinil
Second-line / adjunct
Physical, occupational, and speech therapy
Caregiver education and support; advance care planning early in disease course
Complications
Falls and fractures
Aspiration pneumonia (later disease)
Severe medication intolerance
Neuroleptic sensitivity reaction
Profound autonomic failure
Depression and suicide risk
PANCE pearls
Do NOT give haloperidol or other typical antipsychotics to a patient with DLB — life-threatening sensitivity reaction can result.
Acting out dreams (RBD) often precedes cognitive symptoms by years and is one of the strongest premotor markers of a synucleinopathy.
Cognitive fluctuation can mimic delirium — ask the family if the patient has 'good days and bad days.'
Cholinesterase inhibitors are particularly effective in DLB (more so than in AD).
The 1-year rule: cognitive impairment before or within 1 year of parkinsonism = DLB; parkinsonism >1 year before cognitive impairment = Parkinson disease dementia.
References
McKeith 2017 — McKeith IG et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017;89:88-100.
AAN 2018 — AAN Practice Guideline Summary: Disclosure of dementia diagnosis (overview).
Pimavanserin (HARMONY) — Tariot PN et al. Trial of Pimavanserin in Dementia-Related Psychosis. NEJM 2021;385:309-319.
Practice Neurology questions on FirstPassPA
Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.